Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro
Katie Hege-Hurrish, Yongwei Su, Shraddha Patel, Cassandra L. Ramage, Jianlei Zhao, Brianna R. Temby, Jenna L. Carter, Holly Edwards, Steven Buck, Sandra E. Wiley, Maik Hüttemann, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Xun Bao, Jing Li, Jay Yang, Julie L. Boerner, Zhanjun Hou, Gheath Alatrash, Sergej Konoplev, Jonathan Busquets, Stefano Tiziani, Larry H. Matherly, Jeffrey W. Taub, Marina Konopleva, Yubin Ge, Natalia Baran
Topics & Concepts
CytarabineVenetoclaxMyeloid leukemiaVenPharmacologyLeukemiaCancer researchPurine analogueMedicineBiologyPurineImmunologyChronic lymphocytic leukemiaBiochemistryEnzymeComputer scienceComputer securityAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchCancer therapeutics and mechanisms